ROCKLATAN

Peak

netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%

NDAOPHTHALMICSOLUTION/DROPS

Approved

Mar 2019

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Pharmacologic Class:

Prostaglandin Analog

NCT07174401Phase 4Not Yet Recruiting

Rocklatan Retinal Perfusion OCT Study

Started Jan 2026

30 enrolled

Glaucoma

NCT07325240Phase 4Active Not Recruiting

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

Started Nov 2025

30 enrolled

Open Angle GlaucomaOcular Hypertension

NCT06441643Phase 2Completed

Next Generation Rocklatan

Started Sep 2024

426 enrolled

Open Angle GlaucomaOcular Hypertension

LOE Date

Mar 14, 2034

97 months away

Patent Expiry

Mar 14, 2034

Patent #	Expiry	Type	Use Code
10882840	Jul 11, 2026		U-1524
8450344	Jul 11, 2026	SubstanceProduct	U-1524
9096569	Jul 11, 2026	SubstanceProduct	U-1524
10532993	Jul 11, 2026		U-1524
11021456	Jul 11, 2026		U-1524

Company

External Resources